Genexine Inc (095700) - Total Liabilities

Latest as of September 2025: ₩106.21 Billion KRW ≈ $71.98 Million USD

Based on the latest financial reports, Genexine Inc (095700) has total liabilities worth ₩106.21 Billion KRW (≈ $71.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Genexine Inc operating cash flow efficiency to assess how effectively this company generates cash.

Genexine Inc - Total Liabilities Trend (2009–2024)

This chart illustrates how Genexine Inc's total liabilities have evolved over time, based on quarterly financial data. Check Genexine Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Genexine Inc Competitors by Total Liabilities

The table below lists competitors of Genexine Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Sea Sonic Electronics Co Ltd TWO:6203	Taiwan	NT$925.19 Million
Seronics Co. Ltd KQ:042600	Korea	₩118.34 Billion
Astec LifeSciences Limited NSE:ASTEC	India	Rs4.69 Billion
Waton Financial Limited Ordinary Shares NASDAQ:WTF	USA	$5.31 Million
STLLR Gold Inc. TO:STLR	Canada	CA$8.05 Million
Premia S.A. AT:PREMIA	Greece	€457.50 Million
Ferro S.A. WAR:FRO	Poland	zł380.80 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Genexine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genexine Inc (095700) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.58	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.41	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genexine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genexine Inc (2009–2024)

The table below shows the annual total liabilities of Genexine Inc from 2009 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩83.36 Billion ≈ $56.49 Million	+4.62%
2023-12-31	₩79.68 Billion ≈ $54.00 Million	-29.25%
2022-12-31	₩112.63 Billion ≈ $76.33 Million	-5.45%
2021-12-31	₩119.12 Billion ≈ $80.73 Million	+94.32%
2020-12-31	₩61.30 Billion ≈ $41.54 Million	+0.06%
2019-12-31	₩61.27 Billion ≈ $41.52 Million	+12.82%
2018-12-31	₩54.30 Billion ≈ $36.80 Million	+102.44%
2017-12-31	₩26.83 Billion ≈ $18.18 Million	-5.77%
2016-12-31	₩28.47 Billion ≈ $19.29 Million	+74.28%
2015-12-31	₩16.33 Billion ≈ $11.07 Million	-6.94%
2012-12-31	₩17.55 Billion ≈ $11.89 Million	+15.89%
2011-12-31	₩15.14 Billion ≈ $10.26 Million	+34.71%
2010-12-31	₩11.24 Billion ≈ $7.62 Million	+162.52%
2009-12-31	₩4.28 Billion ≈ $2.90 Million	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$167.36 Million

₩246.95 Billion KRW

Market Cap Rank

#17197 Global

#780 in Korea

Share Price

₩5430.00

Change (1 day)

-3.04%

52-Week Range

₩4280.00 - ₩7100.00

All Time High

₩131402.78